- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05340257
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
May 22, 2023 updated by: GlaxoSmithKline
An Open Label, Single Arm Study, to Evaluate the Pharmacokinetics and Safety of Augmentin Extra Strength (ES)-600 Suspension in Children Presenting With Community Acquired Pneumonia (CAP) and Acute Bacterial Rhinosinusitis (ABRS) in Brazil
The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through treatment emergent adverse event (TEAE) and to explore primary and secondary clinical response of treatment with Augmentin ES in pediatric population presenting with CAP and ABRS in Brazil.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 months to 12 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol.
- In accordance with regional/local laws and regulations,
- a. the parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has
- b.given written assent, if applicable, to participate in the study (for participants between 7 to 12 years)
- Age: Participant must be aged greater than or equal to (>=) 3 months to 12 years, of either gender.
- Participants who are otherwise healthy and presenting with suspected CAP.
- For participants clinically suspected of CAP, at least 3 of the following 4 criteria are applicable:
- a) History of productive cough and/or shortness of breath.
- b)Fever greater than (>)38.5 degree Celsius (○C) (Axillary temperature)
- c) Tachypnea as defined by Respiratory rate (RR) >= 50 breaths/minute in children up to 11 months RR >= 40 breaths/minute in children from 12 months onwards
- d) Chest X-Ray with shadow or lobar condensation, unilateral or bilateral.
For participants of ABRS:
- The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol.
- In accordance with regional/local laws and regulations,
- a..The parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has
- b. given written assent, if applicable, to participate in the study (for participants between 7 to 12 years).
- Age: Participant must be between >=3 months to 12 years of either gender.
- Participants who are otherwise healthy and presenting with suspected ABRS.
- For participants of clinically suspected ABRS, the participants would be eligible if any of the following 2 of the 3 criteria stated below are met:
- a.Children with purulent nasal discharge or daytime productive cough (which may worsen at night) or both persisting for 10 days or more without evidence of improvement.
- b. Fever > 38.3○C (Axillary temperature)
- c. Double sickness defined as initial improvement of symptoms and further worsening/ deterioration after 5 days.
Exclusion Criteria:
- Severe ABRS/CAP requiring hospitalization.
- Currently receiving or has received more than one dose of systemic antibiotic therapy within one week prior to the initiation of the study.
- A serious underlying disease as per clinician's judgment.
- Human immunodeficiency virus (HIV) infection/or any other immunosuppressive condition
- Pre-existing renal insufficiency (for example [e.g.], plasma creatinine > 1.5 times upper limit of normal range for age).
- Pre-existing liver disease(s) and/or hepatic dysfunction.
- Any pre-existing malignancy/any participants undergoing any kind of chemotherapy.
- Evidence of leukopenia and/or thrombocytopenia.
- History of previous hypersensitivity reaction to penicillins, cephalosporins or other Beta-lactam antibiotics.
- History of amoxicillin-clavulanate associated cholestatic jaundice/hepatic dysfunction.
- History of phenylketonuria or a known hypersensitivity to aspartame.
- Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter bowel function.
- Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter renal function like probenecid.
- Participants who have chronic sinusitis (signs and symptoms lasting greater than 28 days prior to screening visit.
- Significant abnormalities of the sinuses and any complications of ABRS.
- Have concurrent streptococcal pharyngitis or acute otitis media (as the standard doses for both of these conditions is 10 days).
- Any other infection or condition, which necessitates use of a concomitant systemic antimicrobial.
- History of infectious mononucleosis.
- History of pseudomembranous colitis.
- Participants that are on warfarin therapy.
- Receipt of an investigational compound (non-food and drug administration [FDA] and non-Brazil National Health Surveillance Agency [ANVISA] approved) or device within the previous 30 days or five half-lives, whichever is longer, preceding the first dose of study intervention or during the study.
- Participants with symptoms suggestive of active Coronavirus disease 2019 (COVID-19) infection (that is (i.e.), fever, cough, etc.)
- Participants with known COVID-19 positive contacts within the past 14 days.
- Female participants who have attained menarche
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants with CAP and ABRS
|
Amoxicillin and clavulanic acid in fixed dose combination will be administered
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absorption rate constant (Ka) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
Area under the serum concentration-time curve (AUC) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
Maximum serum concentration (Cmax) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
Clearance (CL) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
Volume of distribution (Vd) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
Terminal half-life (t1/2) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with treatment emergent adverse events (TEAE)
Time Frame: Up to Day 14
|
Up to Day 14
|
Number of participants achieving Primary Clinical Response
Time Frame: Day 11 to Day 14
|
Day 11 to Day 14
|
Number of participants achieving Secondary Clinical response
Time Frame: Day 22 to Day 28
|
Day 22 to Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 23, 2023
Primary Completion (Anticipated)
January 17, 2024
Study Completion (Anticipated)
January 17, 2024
Study Registration Dates
First Submitted
April 15, 2022
First Submitted That Met QC Criteria
April 15, 2022
First Posted (Actual)
April 22, 2022
Study Record Updates
Last Update Posted (Actual)
May 23, 2023
Last Update Submitted That Met QC Criteria
May 22, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 215335
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD for this study will be made available via the Clinical Study Data Request site.
IPD Sharing Time Frame
IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Bacterial
-
Sir Run Run Shaw HospitalUniversity of BirminghamUnknown
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineWithdrawn
Clinical Trials on Augmentin ES
-
GlaxoSmithKlineIqvia Pty LtdCompletedRespiratory Tract Infections | Otitis Media | Infections, Respiratory TractIndia
-
Swiss Paraplegic Centre NottwilCompletedOrthostatic Hypotension | Spinal Cord InjurySwitzerland
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFecal Incontinence | Bowel IncontinenceUnited States
-
McGuire Research InstituteUnknown
-
Ottawa Heart Institute Research CorporationRecruitingCardiac DiseaseCanada
-
ES Therapeutics Australia Pty LtdRecruitingTremor, EssentialCanada
-
Tarbiat Modarres UniversityCompletedDiabetic FootIran, Islamic Republic of
-
ES Therapeutics Australia Pty LtdWithdrawn
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedCrohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease
-
Afyonkarahisar Health Sciences UniversityCompletedAnemia | Oxidative Stress